Dupilumab Was Well Tolerated and Significantly Improved Atopic Dermatitis in Children Aged ≥ 6 to < 12 Years: Results From the LIBERTY AD PEDS Phase 3 Trial
D. Marcoux, Jashin J. Wu, B. Shumel, Y. Ohya, A. Zhang, Zhen Chen
{"title":"Dupilumab Was Well Tolerated and Significantly Improved Atopic Dermatitis in Children Aged ≥ 6 to < 12 Years: Results From the LIBERTY AD PEDS Phase 3 Trial","authors":"D. Marcoux, Jashin J. Wu, B. Shumel, Y. Ohya, A. Zhang, Zhen Chen","doi":"10.1542/PEDS.147.3_MEETINGABSTRACT.300","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":228253,"journal":{"name":"Section on Advances in Therapeutics and Technology Program","volume":"12 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Section on Advances in Therapeutics and Technology Program","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1542/PEDS.147.3_MEETINGABSTRACT.300","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}